Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies Meeting Abstract
| Authors: | Zelenetz, A. D.; Soumerai, J. D.; Jagadeesh, D.; Reddy, N.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Jhangiani, H.; Iasonos, A.; Krish, P.; Ghalie, R. G.; Pagel, J. M. |
| Abstract Title: | Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454842800093 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-115670 |
| Notes: | Meeting Abstract: 2893 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
